-
Product Insights
NewEsophageal Diseases – Drugs In Development, 2024
Empower your strategies with our Esophageal Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle...
-
Product Insights
NewEsophagitis – Drugs In Development, 2024
Empower your strategies with our Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Esophagitis is inflammation of the esophagus, often triggered by acid reflux, infections, medications, or allergies. Symptoms include painful swallowing, heartburn, chest pain, and sometimes bleeding. Common types include reflux esophagitis (due to GERD) and infectious esophagitis (caused by viruses, fungi, or bacteria). Diagnosis involves endoscopy and sometimes imaging tests. Treatment focuses on addressing the underlying cause, using acid-suppressing medications, antibiotics, antifungals, or lifestyle...
-
Product Insights
NewDuodenal Ulcer – Drugs In Development, 2024
Empower your strategies with our Duodenal Ulcer – Drugs In Development, 2024 report and make more profitable business decisions. Duodenal ulcers, a subset of peptic ulcer disease, result from a disruption in the mucosal surface of the duodenum, the initial segment of the small intestine. The primary culprit behind this condition is infection with Helicobacter pylori (H. pylori) bacteria. H. pylori induces inflammation in the duodenal lining, leading to ulcer formation. Certain medications, especially anti-inflammatory drugs like ibuprofen and aspirin, can...
-
Product Insights
NewThrombosis – Drugs In Development, 2024
Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a...
-
Product Insights
NewSkin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024
Empower your strategies with our Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024 report and make more profitable business decisions. Skin and Skin Structure Infections (SSSIs) caused by bacteria encompass a spectrum of infections affecting the skin and underlying tissues, varying from mild to severe and instigated by diverse bacteria. Notable culprits include Staphylococcus aureus, including methicillin-resistant strains (MRSA), Streptococcus pyogenes (group A Streptococcus), and other streptococcal species. SSSI can manifest as cellulitis, erysipelas, impetigo,...
-
Product Insights
NewOveractive Bladder – Drugs In Development, 2024
Empower your strategies with our Overactive Bladder – Drugs In Development, 2024 report and make more profitable business decisions. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feeling a sudden urge to urinate that's difficult to control, experiencing urge incontinence, and awakening two or more times in the night to urinate. Treatment includes...
-
Product Insights
NewMyocardial Infarction – Drugs In Development, 2024
Empower your strategies with our Myocardial Infarction – Drugs In Development, 2024 report and make more profitable business decisions. Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest; jaw pain, toothache, or headache; shortness of breath; nausea, vomiting, and/or general epigastric discomfort; sweating, heartburn and/or indigestion; arm pain; upper back pain; and general malaise (vague feeling of illness). The Myocardial Infarction drugs in development market research report...
-
Product Insights
NewCorrosive Esophagitis (Erosive Esophagitis) – Drugs In Development, 2024
Empower your strategies with our Corrosive Esophagitis (Erosive Esophagitis) – Drugs In Development, 2024 report and make more profitable business decisions. Erosive esophagitis is the damage caused to the tissue lining. It occurs because of the reflux of gastric contents into the stomach leading to mucosal injury. It is otherwise called as corrosive esophagitis whichis the severe form of gastroesophageal reflux disease (GERD). The Corrosive Esophagitis (Erosive Esophagitis) drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024
Empower your strategies with our Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...